Therapeutic Areas

Edoxaban monotherapy lowered the risk of adverse outcomes, including death from any cause, myocardial infarction, stroke, and systemic embolism at 12 months compared to the dual antithrombotic therapy approach in patients with atrial fibrillation and stable coronary artery disease.

The first-in-class, investigational RNA interference drug plozasiran was found to lower triglyceride levels and incidence of pancreatitis compared to placebo in patients with persistent chylomicronemia, including patients with familial chylomicronemia syndrome.

Crinecerfont was granted previously granted FDA Priority Review designation to treat children, adolescents, and adults with classic congenital adrenal hyperplasia.

Investigators conclude that policies seeking to lower rates of diabetes may also contribute to the goal of ending tuberculosis.

Elinzanetant was found to significantly lower the frequency and severity of moderate to severe vasomotor symptoms with statistically significant improvements in sleep disturbances and menopause-related quality of life.

Mild or moderate acute kidney injury has been linked to increased morbidity and mortality, with a greater risk of chronic kidney disease in patients who undergo cardiac surgery with cardiopulmonary bypass.

Phase III REST-ON trial data show higher rates of weight loss in patients administered Lumryz to treat both narcolepsy type 1 (with cataplexy) and narcolepsy type 2 (without cataplexy) compared with placebo.

Patients administered tirzepatide (Zepbound and Mounjaro; Eli Lilly) also achieved sustained weight loss in Phase III trial, with individuals administered the 15 mg dose showing a 22.9% average reduction in body weight compared with 2.1% among those receiving placebo.

Results show nipocalimab could address the high unmet need of patients with severe hemolytic disease of the fetus and newborn, which is a life-threatening and rare condition with no other therapies currently in clinical development.

Phase IV study finds antihypertensive therapy guided by ambulatory blood pressure monitoring improves target organ damage in patients with masked hypertension.

Webinar Date/Time: Tuesday, August 27, 2024 at 11:00 AM EDT | 8:00 AM PDT | 4:00 PM BST | 5:00 PM CEST

Randomized trial finds once daily oral semaglutide 50 mg lowered energy intake, appetite, and food cravings, with improved control of eating and clinically meaningful reductions in body weight after 20 weeks.

Phase IIb trial indicates liraglutide (Novo Nordisk) may reduce cognitive decline associated with Alzheimer disease by protecting against shrinkage in areas of the brain controlling memory, learning, language, and decision-making.

Randomized trial shows Farxiga improved right ventricular pulsatile afterload and myocardial performance during exercise in patients with heart failure with preserved ejection fraction.

Results from an induction trial and maintenance trial show Skyrizi (risankizumab) improved endoscopic and histological secondary outcomes characterized by endoscopic improvement, remission, and histological, endoscopic, and mucosal improvements in patients with moderately to severely active ulcerative colitis.

Antibody-mediated rejection is the primary cause of kidney allograft failure following kidney transplantation.

Study finds a potential risk of adverse events associated with long-term use of oral corticosteroids in patients with exacerbations of atopic dermatitis.

Paxlovid was the first oral drug approved by the FDA to treat Covid-19 in adults who do not require supplemental oxygen and who have an increased risk of progression to severe disease.

Altuviiio is a first-in-class, high-sustained factor VIII replacement therapy, indicated for routine prophylaxis and on-demand treatment to control bleeding episodes in adults and children with hemophilia.

Study shows patients 80 years and older with atrial fibrillation treated with a lower dose of edoxaban experienced fewer major gastrointestinal bleeding events for each additional ischemic stroke.

Phase III RAISE trial shows superiorty of reteplase over alteplase in improving patients’ functional outcomes without increasing incidence of symptomatic intracranial hemorrhage and death from ischemic stroke within 4.5 hours after symptom onset.

In a Phase I-II trial, CM313 was found to inhibit antibody-dependent cell-mediated cytotoxicity on platelets while achieving long-term efficacy in patients with immune thrombocytopenia.

Study findings suggest that campaigns starting each year at the beginning of respiratory syncytial virus outbreaks, instead of continuous treatment of newborns throughout the year, may improve the usefulness of the Beyfortus program.

Phase III NOTUS trial data show patients with chronic obstructive pulmonary disease and type 2 inflammation administered Dupixent experienced reduced exacerbations and superior lung function compared to placebo.

Patients administered donidalorsen experienced a lower hereditary angioedema (HAE) attack rate, which indicates the potential for prophylactic use in treating HAE.

Phase III trial results show a greater proportion of children aged one to 11 years administered a weight-tiered higher dose of Dupixent achieved a significant improvement across multiple key disease measures for eosinophilic esophagitis compared to placebo.

Phase III SURMOUNT-OSA trial data show positive impact of tirzepatide in patients with moderate-to-severe obstructive sleep apnea and obesity.

Omnipod 5 Automated Insulin Delivery System shows improvements in blood glucose outcomes and overall quality of life among patients with type 2 diabetes.

Tremfya (guselkumab) subcutaneous induction therapy shows positive findings for the treatment of adult patients with moderately to severely active Crohn disease.

The FDA approved HyQvia earlier this year as a maintenance therapy to protect against relapse of neuromuscular disability and impairment in adult patients with chronic inflammatory demyelinating polyneuropathy.